The IL-15 Superagonist ALT-803 Enhances Anti-Cd20 Antibody-Directed NK Cell ADCC and in Vivo Clearance of B Cell Lymphomas

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-2-s3-p168
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Combining ROR1- Specific Chimeric Antigen Receptor (CAR) NK Cells With IL-15 Superagonist (N-803/Alt-803) to Target Chemotherapy Resistant Neuroblastoma

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Combining Dinutuximab With ALT-803 (IL-15 Superagonist) Significantly Improves the Activity of Ex Vivo Expanded Natural Killer Cells Against GD2 + Pediatric Solid Tumors (ST)

Biology of Blood and Marrow Transplantation
TransplantationHematology
2018English

Elotuzumab Directly Enhances NK Cell Cytotoxicity Against Myeloma via CS1 Ligation: Evidence for Augmented NK Cell Function Complementing ADCC

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2013English

Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models

Cancer immunology research
Cancer ResearchImmunology
2015English

Adipocyte IL-15 Regulates Local and Systemic NK Cell Development

Journal of Immunology
AllergyImmunology
2014English

ADCC-Mediated CD56dim NK Cell Responses Are Associated With Early HBsAg Clearance in Acute HBV Infection

Pathogens and Immunity
2018English

The Diagnosis and Management of NK/T-cell Lymphomas

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2017English

B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2003English

Antibody-Targeted Paclitaxel Loaded Nanoparticles for the Treatment of CD20+ B-Cell Lymphoma

Scientific Reports
Multidisciplinary
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy